Hobart Group member, Molecular Dynamics, has reported positive results from its first phase clinical trial of the Valiance X12 whole-body Cadmium Zinc Telluride (CZT) based digital SPECT/CT prototype.
Valiance X12 has been designed as a whole-body CZT SPECT/CT solution to generate scans compared to positron emission tomography (PET) at a higher speed, lower dose and reduced cost.
Its wide band capabilities facilitate multi-function imaging while it enhances productivity and image quality due to improved resolution and sensitivity which is a result of its Cadmium Zinc Telluride (CZT) based technology.
The design of the device enables independent radial swivel motion, gantry rotation and adaptive image acquisition, which aim the detectors on target areas, offering multiple angular views and enhanced images of a target.
Valiance X12 is based on a proprietary adaptive image acquisition mechanism which modulates the movement of each detector to ensure efficient data acquisition and uses proprietary algorithms for optimal image reconstruction and quantification.
The study, which was conducted at Chaim Sheba Medical Center in Israel, was intended to examine the image quality and diagnostic performance of the Valiance X12.
The device was used to generate digital SPECT scans from 25 patients who had previously undergone analog SPECT scans, under the supervision of Dr Ronen Goldkorn and Dr Elinor Goshen.
Analysis of the images suggested that Valiance X12 offers improved image resolution and contrast.
Dr Goshen said: “These findings are promising for CZT-based digital SPECT.
“Further research will assess other general Nuclear Medicine applications, as well as the contribution of focused imaging, a unique capability of the Valiance X12.”
The results of the study with additional findings will be presented at the European Association of Nuclear Medicine Annual Congress in Barcelona, Spain.
Image: Study images of a 35 year old male with right ankle pain. Photo: courtesy of Hobart Group.